RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $148.00.

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of ...

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment ...

Neurocrine Biosciences stock opened at $150.10 on Tuesday. The stock has a market cap of $15.20 billion, a price-to-earnings ratio of 40.24 and a beta of 0.33. The company’s 50-day moving ...

Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market cap of $15.20 billion, a P/E ratio of 40.24 and a beta of 0.33. Analyst Upgrades and ...

Visa and Abbott are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These products and services ...

On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00.

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...